Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NKTR 
Nektar Therapeutics (NKTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/04/2025: NKTR (4-star) is a REGULAR-BUY. BUY since 92 days. Simulated Profits (88.75%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $93.86
1 Year Target Price $93.86
| 2 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 125.31% | Avg. Invested days 42 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.14B USD | Price to earnings Ratio - | 1Y Target Price 93.86 |
Price to earnings Ratio - | 1Y Target Price 93.86 | ||
Volume (30-day avg) 8 | Beta 1.28 | 52 Weeks Range 6.45 - 66.92 | Updated Date 11/4/2025 |
52 Weeks Range 6.45 - 66.92 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.08 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -163.17% | Operating Margin (TTM) -320.21% |
Management Effectiveness
Return on Assets (TTM) -31.57% | Return on Equity (TTM) -440.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1070876666 | Price to Sales(TTM) 15.22 |
Enterprise Value 1070876666 | Price to Sales(TTM) 15.22 | ||
Enterprise Value to Revenue 14.29 | Enterprise Value to EBITDA -6.5 | Shares Outstanding 19018573 | Shares Floating 17594272 |
Shares Outstanding 19018573 | Shares Floating 17594272 | ||
Percent Insiders 0.71 | Percent Institutions 51.65 |
Upturn AI SWOT
Nektar Therapeutics
Company Overview
History and Background
Nektar Therapeutics was founded in 1990. It initially focused on inhaled drug delivery technologies before evolving into a biopharmaceutical company developing its own pipeline of drug candidates.
Core Business Areas
- Drug Development: Nektar focuses on discovering and developing innovative medicines. Their pipeline includes programs across oncology, immunology, and other disease areas.
- Technology Platform: Nektar leverages its proprietary PEGylation technology platform to create new molecular entities with improved pharmacokinetic and pharmacodynamic properties.
Leadership and Structure
Nektar's leadership includes a CEO, CFO, and other key executives. The organizational structure is based on functional areas like research, development, and commercialization.
Top Products and Market Share
Key Offerings
- BEMPEG (Pegilodecakin): BEMPEG was Nektar's lead immuno-oncology candidate, designed to stimulate proliferation of anti-tumor T cells. However, its clinical development was discontinued after disappointing Phase 3 results. Previously estimated market potential was several billion USD annually. Bristol Myers Squibb was a partner on this and the competitors would have been other IO companies such as Merck, Roche, and AstraZeneca.
- Market Data: Clinical development discontinued.
- Market Data: Currently in clinical trials. Future market potential unknown.
- NKTR-358: NKTR-358 is a novel IL-2 cytokine receptor agonist being developed for autoimmune diseases. The drug is partnered with Eli Lilly who is responsible for all clinical development, regulatory approval and commercialization. Competing autoimmune biologics exist from companies such as AbbVie and Amgen.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. Innovation and strategic partnerships are crucial for success.
Positioning
Nektar aims to create novel therapies using its PEGylation technology platform. Its competitive advantage was to focus on novel therapeutic candidates, now they have to rebuild the portfolio. Focus is on partnerships.
Total Addressable Market (TAM)
The total addressable market depends on the individual drugs under development. Immuno-oncology and autoimmune diseases represent multi-billion dollar markets. Nektar's positioning depends on the success of their partnered and internal programs.
Upturn SWOT Analysis
Strengths
- Proprietary PEGylation technology platform
- Partnerships with major pharmaceutical companies (Eli Lilly)
- Experienced research and development team
Weaknesses
- High dependence on partnered programs
- Pipeline risk due to the nature of drug development
- History of clinical trial setbacks
Opportunities
- Expanding partnerships with other pharmaceutical companies
- Developing new applications for the PEGylation technology platform
- Advancements in targeted therapies and personalized medicine
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- MRK
- BMY
- ABBV
- LLY
Competitive Landscape
Nektar faces intense competition from established pharmaceutical companies with larger R&D budgets and broader product portfolios. Nektar needs to execute successful programs to keep up.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to clinical trial setbacks.
Future Projections: Future growth depends on the success of NKTR-358 with Eli Lilly and other partnered programs.
Recent Initiatives: Focusing on strategic partnerships to advance its pipeline and reduce financial risk.
Summary
Nektar Therapeutics is a biopharmaceutical company focused on drug discovery and development. The company's past has seen clinical trial failures and high dependence on strategic partnerships. The main objective now is to create successful partnered programs like NKTR-358 to drive value. Nektar faces competition from larger pharmaceutical companies and needs to secure partnerships to fund its pipeline. Future growth depends on successful clinical trials and commercialization of its drug candidates.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Various Market Data Sources
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and thorough research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nektar Therapeutics
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 1994-05-03 | CEO, President & Director Mr. Howard W. Robin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.nektar.com |
Full time employees 61 | Website https://www.nektar.com | ||
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.